Austin, Texas-based Flat designed EpiFaith to transform epidural procedures, according to a news release. It converts the tactile loss-of-resistance technique into an objective visual signal. The breakthrough technology enables anesthesia providers to identify the epidural space more accurately while keeping both hands free. This provides optimal needle control to help reduce the risk of accidental dural puncture and related complications.
“This partnership with Mercury Medical represents a significant step in expanding our reach to healthcare providers across America,” said Mark Rabe, Director of Sales and Distribution at Flat Medical. “Mercury Medical’s comprehensive sales team and deep market expertise provide us with the specialized resources to penetrate hospitals nationwide and deliver EpiFaith technology to clinicians who need it most.”
The distribution deal allows Mercury to bring the EpiFaith technology to the U.S. anesthesia market. Mercury brings more than 60 years of experience in clinical equipment markets. It also specializes in airway management and respiratory equipment.
Flat Medical said the partnership leverages Mercury’s comprehensive sales force and extensive U.S. distribution network. Combining it with the proven safety technology can help accelerate market penetration and reach hospitals nationwide.
“We are excited to partner with Flat Medical to bring this groundbreaking epidural safety technology to our customers,” said John Gargaro, M.D., CEO and President of Mercury Medical. “The EpiFaith smart syringe aligns perfectly with our mission to deliver clinically differentiated critical care technology that saves lives.”
